Paul N. Durrington

36.3k citations

287 papers · 19.9k indexed · 6 hit papers · h-index 68

Impact in

Clinical Biochemistry top 0.01%
- Paraoxonase enzyme and polymorphisms
Endocrinology, Diabetes and Metabolism top 0.05%
- Diabetes, Cardiovascular Risks, and Lipoproteins

Papers in

Clinical Biochemistry 65
- Paraoxonase enzyme and polymorphisms 54
Endocrinology, Diabetes and Metabolism 131
- Diabetes, Cardiovascular Risks, and Lipoproteins 109

Co-authors: Michael I. Mackness Bharti Mackness Valentine Charlton-Menys Sharon Arrol Mike Mackness Helen M. Colhoun G. A. Hitman D. J. Betteridge
Journals: Atherosclerosis (50 papers)Current Opinion in Lipidology (24 papers)Diabetic Medicine (12 papers)Clinical Science (10 papers)The Lancet (7 papers)
Partner nations: United Kingdom United States Qatar

In The Last Decade

Paul N. Durrington

282 papers receiving 19.0k citations

Hit Papers

6 papers align trajectories log scale

Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins 2012 · 577 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2012 JAMA
2011 Atherosclerosis
2004 The Lancet
2001 Arteriosclerosis Thrombosis and Vascular Biology
2000 Nature Genetics
1991 Atherosclerosis

Peers

Countries citing papers authored by Paul N. Durrington

Since Specialization

Citations

This map shows the geographic impact of Paul N. Durrington's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul N. Durrington with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul N. Durrington more than expected).

Fields of papers citing papers by Paul N. Durrington

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul N. Durrington. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul N. Durrington. The network helps show where Paul N. Durrington may publish in the future.

Co-authors

The 25 scholars most cited alongside Paul N. Durrington, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Paul N. Durrington Line = papers co-authored together Paul N. Durrington links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Ethnic Diversity and Distinctive Features of Familial Versus Multifactorial Chylomicronemia Syndrome: Insights From the UK FCS National Registry Arteriosclerosis Thrombosis and Vascular Biology ·Bilal Bashir, Paul Downie, Natalie Forrester, Anthony S. Wierzbicki, Charlotte Dawson, Alan G. Jones, Fiona Jenkinson, Michael Mansfield, D. Datta, Hannah Delaney, Yee Teoh, Paul Hamilton, Maryam Ferdousi, See Kwok, Dawn O’Sullivan, Jian Wang, Robert A. Hegele, Paul N. Durrington, Handrean Soran	2024	8
2	Severe Hypertriglyceridaemia and Chylomicronaemia Syndrome—Causes, Clinical Presentation, and Therapeutic Options Metabolites ·Bilal Bashir, Jan Hoong Ho, Paul Downie, Paul Hamilton, Gordon A. Ferns, D. Datta, Jaimini Cegla, Anthony S. Wierzbicki, Charlotte Dawson, Fiona Jenkinson, Hannah Delaney, Michael Mansfield, Yee Teoh, Zosia Miedzybrodzka, Haya Haso, Paul N. Durrington, Handrean Soran	2023	22
3	Glycated apolipoprotein B decreases after bariatric surgery in people with and without diabetes: A potential contribution to reduction in cardiovascular risk Atherosclerosis ·Zohaib Iqbal, Bilal Bashir, Safwaan Adam, Jan Hoong Ho, Shaishav Dhage, Shazli Azmi, Maryam Ferdousi, Zahid Yusuf, Rachelle Donn, Rayaz A. Malik, Akheel A. Syed, Basil J. Ammori, Adrian Heald, Paul N. Durrington, Handrean Soran	2022	8
4	Alcohol and Health: Social Evolution, Production and Control Paul N. Durrington, Handrean Soran, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2021	1
5	Serum kidney injury molecule 1 and β2-microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes Diabetologia ·(unknown), Marco Colombo, Helen C. Looker, Bassam Farran, Sibylle Hess, Leif Groop, (unknown), M. Julia Brosnan, R. Neil Dalton, Max Wong, Charles Turner, Emma Ahlqvist, David B. Dunger, Felix Agakov, Paul N. Durrington, Shona Livingstone, John Betteridge, Paul McKeigue, Helen M. Colhoun	2018	52
6	Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial Diabetologia ·(unknown), Sabita S. Soedamah‐Muthu, Shona Livingstone, Valentine Charlton-Menys, D. J. Betteridge, G. A. Hitman, H. A. W. Neil, Weihang Bao, David A. DeMicco, Gregory M. Preston, John Fuller, Coen D.A. Stehouwer, Casper G. Schalkwijk, Paul N. Durrington, Helen M. Colhoun	2015	30
7	Unintended positive and negative effects of drugs on lipoproteins Current Opinion in Lipidology ·Tarza Siahmansur, Jonathan Schofield, Shazli Azmi, Yifen Liu, Paul N. Durrington, Handrean Soran	2015	3
8	How HDL protects LDL against atherogenic modification Current Opinion in Lipidology ·Handrean Soran, Jonathan Schofield, Yifen Liu, Paul N. Durrington	2015	32
9	C-reactive Protein and Amyloid A as Predictors of Cardiovascular Events in Type 2 Diabetes in the CARDS Study Circulation ·Valentine Charlton-Menys, Helen M. Colhoun, D. J. Betteridge, S.S. Soedamah-Muthu, G. A. Hitman, AW Neil, Shona Livingstone, Weiping Bao, David A. DeMicco, GM Preston, J. Fuller, Paul N. Durrington	2009	1
10	Triglycerides and small dense low density lipoprotein in the discrimination of coronary heart disease risk in South Asian populations Atherosclerosis ·Jay Patel, Muriel Caslake, Avni Vyas, J. CRUICKSHANK, Dorairaj Prabhakaran, Deepak Bhatnagar, K. Srinath Reddy, Gregory Y.H. Lip, Mike Mackness, Elizabeth Hughes, Paul N. Durrington	2009	16
11	Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS) American Journal of Kidney Diseases ·Helen M. Colhoun, D. J. Betteridge, Paul N. Durrington, G. A. Hitman, H. A. W. Neil, Shona Livingstone, Valentine Charlton-Menys, David A. DeMicco, John Fuller	2009	186
12	Hyperinsulinemia, insulin resistance, and circulating oxidized low density lipoprotein in women with systemic lupus erythematosus. PubMed ·Masoud El Magadmi, Yasmeen Ahmad, Wajdi Turkie, Allen P. Yates, Naseem Sheikh, Robert M. Bernstein, Paul N. Durrington, Ian Laing, Ian N Bruce	2006	95
13	Lipid treatment strategies for metabolic syndrome in established cardiovascular disease: a consensus guideline Practical Diabetes International ·Mat D. Davis, Paul N. Durrington, Waqas Hanif, Jane M. Morrell, S. Mughal, T Mehrali, A H Barnett, J. Shepherd	2006	0
14	Sequencing of the Reannotated LMNB2 Gene Reveals Novel Mutations in Patients with Acquired Partial Lipodystrophy The American Journal of Human Genetics ·Robert A. Hegele, Henian Cao, Dora M. Liu, Gary A. Costain, Valentine Charlton-Menys, N. W. Rodger, Paul N. Durrington	2006	147
15	Prevention of Recurrent Pancreatitis in Familial Lipoprotein Lipase Deficiency with High-Dose Antioxidant Therapy The Journal of Clinical Endocrinology & Metabolism ·Alice Heaney, Nurfadhlina Sharer, Bashir Rameh, Joan M. Braganza, Paul N. Durrington	1999	35
16	Human Serum Paraoxonase General Pharmacology The Vascular System ·Bharti Mackness, Paul N. Durrington, M. Mackness	1998	282
17	Presence of paraoxonase in human interstitial fluid FEBS Letters ·Michael I. Mackness, Bharti Mackness, Sharon Arrol, Grahame Wood, Deepak Bhatnagar, Paul N. Durrington	1997	44
18	Suppression of non-esterified fatty acids to treat type A insulin resistance syndrome The Lancet ·Sudhesh Kumar, Paul N. Durrington, Deepak Bhatnagar, Ian Laing	1994	21
19	A cross-sectional evaluation of cardiovascular risk factors in coronary heart disease associated with Type 1 (insulin-dependent) diabetes mellitus Diabetes Research and Clinical Practice ·Peter Winocour, Paul N. Durrington, Deepak Bhatnagar, Anthony Mbewu, Monica Ishola, M. Mackness, Sharon Arrol	1992	29
20	Rapid screening for specific mutations in patients with a clinical diagnosis of familial hypercholesterolaemia Atherosclerosis ·Philippa J. Talmud, Anne Tybjærg-Hansen, Deepak Bhatnagar, Anthony Mbewu, J. Philip Miller, Paul N. Durrington, Steve E. Humphries	1991	89

About Paul N. Durrington

Paul N. Durrington is a scholar working on Clinical Biochemistry, Endocrinology, Diabetes and Metabolism, Surgery, Cardiology and Cardiovascular Medicine and Biochemistry, having authored 287 papers that have together received 19.9k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (125 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (109 papers), Paraoxonase enzyme and polymorphisms (54 papers), Cancer, Lipids, and Metabolism (34 papers), Lipid metabolism and disorders (31 papers), Health Systems, Economic Evaluations, Quality of Life (30 papers), Cynara cardunculus studies (18 papers) and Biochemical Acid Research Studies (16 papers). The work is most often cited by research in Clinical Biochemistry (5.7k citations), Endocrinology, Diabetes and Metabolism (6.6k citations), Biochemistry (1.8k citations), Surgery (7.6k citations) and Cardiology and Cardiovascular Medicine (3.3k citations). Paul N. Durrington has collaborated with scholars based in United Kingdom, United States and Qatar. Frequent co-authors include Michael I. Mackness, Bharti Mackness, Valentine Charlton-Menys, Sharon Arrol, Mike Mackness, Helen M. Colhoun, G. A. Hitman, D. J. Betteridge, H. A. W. Neil and Shona Livingstone. Their work appears in journals such as Atherosclerosis, Current Opinion in Lipidology, Diabetic Medicine, Clinical Science and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact